BGB 324

Drug Profile

BGB 324

Alternative Names: BGB-324; R-428

Latest Information Update: 12 May 2017

Price : $50

At a glance

  • Originator Rigel Pharmaceuticals
  • Developer BerGenBio; Haukeland University Hospital; University of Texas Southwestern Medical Center
  • Class Antineoplastics; Benzocycloheptenes; Cycloheptanes; Pyridazines; Pyrrolidines; Small molecules; Triazoles
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma; Non-small cell lung cancer
  • Phase I Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Solid tumours
  • Preclinical Pancreatic cancer

Most Recent Events

  • 01 Apr 2017 Preclinical data in Solid tumours presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 08 Mar 2017 BerGenBio and Merck plan a phase II trial for Non-small cell lung cancer (Combination therapy, Metastatic disease, Second-line therapy or greater, Late-stage disease) in Norway, Spain, United Kingdom and USA (PO) (NCT03184571) (EudraCT2016-003609-32)
  • 08 Mar 2017 BerGenBio and Merck plans a phase II trial for Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater, Late-stage disease, Inoperable/Unresectable) in USA, Norway, Spain and United Kingdom (PO) (NCT03184558) (EudraCT2016-003608-30)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top